secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-08-01T23:59:59+00:00
Accession:  0000950170-25-101414
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics updates corporate presentation; no material new data disclosed
--------------------------------------------------------------------------------

- Updated corporate presentation filed August 1, 2025; no new clinical data or financial guidance disclosed.
- Pipeline includes [212Pb]VMT-α-NET for neuroendocrine tumors, VMT01 for melanoma, and PSV359 targeting FAP-α.
- Presentation notes sustained anti-tumor activity and tolerability for NET trial; no quantitative updates.
- Pre-targeting platform and supply chain infrastructure highlighted as key differentiators.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017025101414/0000950170-25-101414-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017025101414/catx-20250801.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-101414

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer